Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the superiority of olanzapine (up to 30 mg/day) plus carbamazepine (400 to 1200 mg/day) versus placebo plus carbamazepine (400 to 1200 mg/day) in improving overall manic symptomatology in patients with mania associated with bipolar I disorder.
Critère d'inclusion
- Manic or Mixed Episodes Associated with Bipolar I Disorder